MX2022001535A - Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. - Google Patents
Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.Info
- Publication number
- MX2022001535A MX2022001535A MX2022001535A MX2022001535A MX2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A
- Authority
- MX
- Mexico
- Prior art keywords
- sepiapterin
- radiation exposure
- metabolites
- treat radiation
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882937P | 2019-08-05 | 2019-08-05 | |
| PCT/US2020/045026 WO2021026247A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001535A true MX2022001535A (es) | 2022-03-04 |
Family
ID=72148243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001535A MX2022001535A (es) | 2019-08-05 | 2020-08-05 | Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220273661A1 (https=) |
| EP (2) | EP4454712A3 (https=) |
| JP (2) | JP7642611B2 (https=) |
| CN (2) | CN114555090B (https=) |
| AU (1) | AU2020324435B2 (https=) |
| BR (1) | BR112022002029A2 (https=) |
| CA (1) | CA3146477A1 (https=) |
| DK (1) | DK4009978T3 (https=) |
| ES (1) | ES2994060T3 (https=) |
| FI (1) | FI4009978T3 (https=) |
| HR (1) | HRP20241653T1 (https=) |
| HU (1) | HUE069012T2 (https=) |
| IL (1) | IL290321B1 (https=) |
| LT (1) | LT4009978T (https=) |
| MX (1) | MX2022001535A (https=) |
| PL (1) | PL4009978T3 (https=) |
| PT (1) | PT4009978T (https=) |
| RS (1) | RS66096B1 (https=) |
| SI (1) | SI4009978T1 (https=) |
| SM (1) | SMT202500089T1 (https=) |
| WO (1) | WO2021026247A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| WO2005048926A2 (en) | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
| KR20070084270A (ko) | 2004-11-17 | 2007-08-24 | 바이오마린 파머수티컬 인크. | 안정한 정제 제형물 |
| TWI359019B (en) * | 2006-08-14 | 2012-03-01 | Merck Eprova Ag | Use of folates for the prevention and treatment of |
| MX379061B (es) | 2013-09-13 | 2025-03-04 | Bioventures Llc | Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion. |
| CN106794197A (zh) | 2014-10-02 | 2017-05-31 | 西托索尔本茨公司 | 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途 |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| CN110354133A (zh) * | 2019-08-26 | 2019-10-22 | 鞍山市肿瘤医院 | 四氢生物蝶呤的应用及药物 |
-
2020
- 2020-08-04 IL IL290321A patent/IL290321B1/en unknown
- 2020-08-05 AU AU2020324435A patent/AU2020324435B2/en active Active
- 2020-08-05 CN CN202080069308.5A patent/CN114555090B/zh active Active
- 2020-08-05 BR BR112022002029A patent/BR112022002029A2/pt unknown
- 2020-08-05 CA CA3146477A patent/CA3146477A1/en active Pending
- 2020-08-05 LT LTEPPCT/US2020/045026T patent/LT4009978T/lt unknown
- 2020-08-05 DK DK20758407.9T patent/DK4009978T3/da active
- 2020-08-05 PL PL20758407.9T patent/PL4009978T3/pl unknown
- 2020-08-05 MX MX2022001535A patent/MX2022001535A/es unknown
- 2020-08-05 SM SM20250089T patent/SMT202500089T1/it unknown
- 2020-08-05 JP JP2022507561A patent/JP7642611B2/ja active Active
- 2020-08-05 CN CN202411691224.1A patent/CN119837879A/zh active Pending
- 2020-08-05 HR HRP20241653TT patent/HRP20241653T1/hr unknown
- 2020-08-05 WO PCT/US2020/045026 patent/WO2021026247A1/en not_active Ceased
- 2020-08-05 RS RS20241189A patent/RS66096B1/sr unknown
- 2020-08-05 EP EP24187395.9A patent/EP4454712A3/en active Pending
- 2020-08-05 SI SI202030521T patent/SI4009978T1/sl unknown
- 2020-08-05 US US17/631,995 patent/US20220273661A1/en active Pending
- 2020-08-05 EP EP20758407.9A patent/EP4009978B1/en active Active
- 2020-08-05 PT PT207584079T patent/PT4009978T/pt unknown
- 2020-08-05 HU HUE20758407A patent/HUE069012T2/hu unknown
- 2020-08-05 FI FIEP20758407.9T patent/FI4009978T3/fi active
- 2020-08-05 ES ES20758407T patent/ES2994060T3/es active Active
-
2025
- 2025-02-26 JP JP2025029508A patent/JP2025098011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555090A (zh) | 2022-05-27 |
| US20220273661A1 (en) | 2022-09-01 |
| EP4454712A3 (en) | 2025-01-01 |
| FI4009978T3 (fi) | 2024-11-01 |
| JP2025098011A (ja) | 2025-07-01 |
| EP4009978A1 (en) | 2022-06-15 |
| HUE069012T2 (hu) | 2025-02-28 |
| EP4009978B1 (en) | 2024-09-25 |
| ES2994060T3 (en) | 2025-01-16 |
| CN119837879A (zh) | 2025-04-18 |
| SI4009978T1 (sl) | 2025-03-31 |
| BR112022002029A2 (pt) | 2022-06-07 |
| CA3146477A1 (en) | 2021-02-11 |
| RS66096B1 (sr) | 2024-11-29 |
| AU2020324435A1 (en) | 2022-02-24 |
| JP2022543655A (ja) | 2022-10-13 |
| IL290321B1 (en) | 2026-04-01 |
| LT4009978T (lt) | 2024-11-25 |
| HRP20241653T1 (hr) | 2025-04-25 |
| PL4009978T3 (pl) | 2025-02-24 |
| PT4009978T (pt) | 2024-11-05 |
| WO2021026247A1 (en) | 2021-02-11 |
| IL290321A (en) | 2022-04-01 |
| CN114555090B (zh) | 2024-12-17 |
| JP7642611B2 (ja) | 2025-03-10 |
| AU2020324435B2 (en) | 2026-03-19 |
| DK4009978T3 (da) | 2024-10-14 |
| SMT202500089T1 (it) | 2025-03-12 |
| EP4454712A2 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001535A (es) | Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. | |
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CO2023010562A2 (es) | Degradadores irak4 y usos de los mismos | |
| MX2019013858A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| CL2017003107A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| MX2017012380A (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| CY1125116T1 (el) | Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου | |
| CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
| CR20190376A (es) | Formulaciones de anticuerpos de her2 subcutáneas | |
| MX2022002954A (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos. | |
| CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
| MX2017016681A (es) | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| ECSP17059323A (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| ECSP21021189A (es) | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso | |
| CL2024000250A1 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| MX2024003655A (es) | Metodos para tratar cancer. | |
| CL2020003118A1 (es) | Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k. | |
| ECSP22043592A (es) | Inhibidores de egfr alost?ricos y m?todos de uso de los mismos | |
| MX2021007177A (es) | Formulacion de inhalacion de polvo seco y su uso para el tratamiento terapeutico de los pulmones. | |
| BR112018009745A8 (pt) | compostos heterocíclicos para o tratamento de doença | |
| BR112017020374A2 (pt) | compostos bicíclicos fundidos para o tratamento de doença |